Deceivers of Drugs Merck and FDA Introduction A blockbuster drug, Rofecoxib, with sales of 2.5 billion dollars of annual sales was pulled off the market (Topol, 2004). The drug was pulled off after epidemiological studies had noted 1.4 million people have had a serious side effect (Medscape Medical News, 2004; Topol, 2004). Rofecoxib side effects were all associated with myocardial infarction, cardiovascular risks, and even death (Smith, 2007; Topol
Introduction: Merck had a reputation of providing the best research in order to find the cure for diseases such as AIDS, tuberculosis, hypertension. They spend on average around $3 billion dollars on research on a yearly basis. However, they needed to produce a drug that would take Merck to the next level. Merck created Vioxx which was designed to treat osteoarthritis and in May 1999, the FDA approved Vioxx making it available with a medical prescription (Snigdha., 2007). During this period
the type of reporting. For example; summary statistics of reports by foreign and domestic countries, summary statistics of reports by healthcare professional and consumers, and summary statistics by manufacturer. In the year of 1962, Kefauver-Harris drug Amendment Act was established. The act stated, all drugs has to undergo strict surveillance during clinical trials and also after drug is marketed out. The clinical trial has to provide data that proves that the drug is both safe and effective before
and underestimation of harm caused by negative results not being published. The famous cover up of anti-inflammatory drug Rofecoxib’s negative effects (Vioxx) is an example of how withholding negative results can hurt patients (Curfman, 2005). Rofecoxib was prescribed to 80 million people. After 5 years, it was revealed that founding company, Merck,... ... middle of paper ... ...formation." Food and Drug Administration Amendments Act (FDAAA) of 2007. FDA, 2 Dec. 2011. Web. 23 Nov. 2013. Scargle
Solubility studies for screening of microemulsion components The solubility of HCA in various oils and surfactants such as eucalyptus oil, clove oil, lemon grass oil, pippermint oil, carvone, D-limonene, citronella, menthone, eugenol, oleic acid, tween 20, isopropyl myristate (IPM), tween 80, polyethylene glycol 400 (PEG 400) were measured. An excess amount of HCA was added to 10mL of oil and the mixture was shaken for 72 h at 25 °C. The resulting suspension was then centrifuged (R-8C REMI equipments
Background Acne vulgaris is the most common cutaneous disorder affecting adolescents and young adults. Acne vulgaris is a disease of pilosabaceous follicles with four pathogenic factors. These factors are follicular hyperkeratinization, increased sebum production, infection with Propionibacterium acnes within the follicle, and resulting inflammation. Follicular hyperkeratinization is increased proliferation and decreased desquamation of keratinocytes lining the follicular orifice. This results
Introduction- What is Etoricoxib? Etoricoxib, also known as Arcoxia1, is more commonly known as a non-steroidal anti-inflammatory drug (NSAID), or as a cyclo-oxygenase-2 inhibitor (COX-2). Therapeutically, it is specified for the ‘symptomatic relief” of conditions such as osteoarthritis (OA), rheumatoid arthritis (RA), ankylosing spondylitis2,3, and overall for their analgesic and anti-inflammatory properties. Arthritis is a chronic disease affecting up to ten million people in the UK. Approximately
The Pathways of Pain In 1931, the French medical missionary Dr. Albert Schweitzer wrote, "Pain is a more terrible lord of mankind than even death itself." Today, pain has become the universal disorder, a serious and costly public health issue, and a challenge for family, friends, and health care providers who must give support to the individual suffering from the physical as well as the emotional consequences of pain (1). Early humans related pain to evil, magic, and demons. Relief of pain
Drug Development: Historical Influences, Recent Trends and Emerging Fields within the Pharmaceutical Industry Introduction In recent years, the cost of drug development has been rising at an unprecedented level. The cost of developing a new drug target was estimated to be $802 million in 2003, having risen from $138 million in 1979 and $318 million in 1991 [1] [2] [3]. These numbers are averages within the industry for the “average drug”. There is variation within the industry with cost estimates